This is a randomized, controlled trial investigating whether immediate versus standard, “Sunday Start”, initiation of oral contracpetive pills (OCPs) in post-abortion subjects can improve compliance and continuation of contraception. Immediate initiation of OCPs has been studied in women seeking contraception when they are not immediately post-abortion, and this “Quick Start” method has been shown to improve continuation of OCPs into a second pill pack. The primary hypothesis of this study is that immediate initiation of OCPs in post-abortal women will improve continuation of contraception over delayed initiation on the first Sunday after abortion.

Condition	Intervention
Abortion Randomized Contraception Pregnancy	Behavior: Immediate versus delayed initiation of OCPs

Further study details as provided by University of California, San Francisco:

Primary Outcomes: Continuation of OCPs after abortion.
Secondary Outcomes: Compliance with OCPs after abortion.; Bleeding patterns on OCPs after abortion.; Satisfaction with OCPs after abortion.
Expected Total Enrollment:  300

The United States has a higher rate of unintended pregnancy than Canada or any other developed nation in Europe. OCPs are the most common method of hormonal contraception used in this country. Perfect use can lead to failure rates as low as 0.1% per year. Actual failure rates are much higher, often due to non-compliance with OCP use. Several recent studies have examined the “Quick Start”, or initiation of OCPs in front of the provider while still at the clinic, regardless of time in the cycle. These studies have shown that women who swallowed the first OCP in the clinic were more likely to continue the OCP into the second month. Women who are seen in clinics for a therapeutic abortion (TAB) are often at extremely high risk for another unintended/unwanted pregnancy. If compliance in OCP use could be improved in this group of women, unintended/unwanted pregnancy rates could be reduced. One concern about the “Quick Start” technique is that women may have already ovulated or conceived when OCPs are initiated mid-cycle. In the post-abortal setting, this is not a concern. Applying the “Quick Start” technique to post-abortion patients and having women take the first of their OCPs while still in the clinic after their abortion may improve compliance and continuation of OCP use.

This is a prospective, randomized, controlled trial in post-abortal women, and will last approximately 24 months. All of the study subjects will receive a single pack of combination OCPs and a one-year prescription after their TAB. The women in the immediate start arm will then take their first OCP in the clinic, observed by clinic staff, before leaving. The controls will be instructed to begin the OCPs on the first Sunday following their abortion. All subjects will receive the same medication with the only difference being the timing of initiation of the OCPs. Measurements of continuation will be determined by telephone interviews administered at two and six months after the subjects’ abortion.

Ages Eligible for Study:  13 Years   -   45 Years,  Genders Eligible for Study:  Female

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

• Any woman age 13-45 who presents to the Women''''s Options Clinic and desires to use OCPS for post-abortion contraception.

Exclusion Criteria:

• Gestational age above 23 weeks and 1 day.
• Any absolute contraindication for combination OCP use (smoking >20 cigarettes a day over age 35, history of venous thromboembolic event or pulmonary embolism, history of or current ischemic heart disease, history of stroke, vascular disease, complicated valvular heart disease (pulmonary hypertension, atrial fibrillation, history of subacute bacterial endocarditis), severe hypertension with blood pressure >160/100, migraines with focal neurologic symptoms, current breast cancer, active viral hepatitis, severe cirrhosis, benign or malignant liver tumors.
• Patients who speak languages other than English or Spanish.
• Patients who do not have a phone or who have a phone where any contact might compromise the confidentiality of their abortions.

Please refer to this study by ClinicalTrials.gov identifier  NCT00235534

Sarah W Prager, MD      (415)206-4473    pragers@obgyn.ucsf.edu
Jody E Steinauer, MD, MAS      (415)206-6528    steinauerj@obgyn.ucsf.edu

California
      Women''''s Options Clinic at San Francisco General Hospital, San Francisco,  California,  94110,  United States

Study chairs or principal investigators

Jody E Steinauer, MD. MAS,  Principal Investigator,  University of California, San Francisco   
Sarah W Prager, MD,  Study Director,  University of California, San Francisco   

Study ID Numbers:  H11779-26464-01
Last Updated:  December 8, 2005
Record first received:  October 6, 2005
ClinicalTrials.gov Identifier:  NCT00235534
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2006-01-10